Impressive sales growth for UZEDY® in Q1 2026

The drug UZEDY®, marketed in the United States, saw its net sales reach $63 million in the first quarter of 2026. This figure represents a 62% increase compared to the previous year. This growth is also significant when compared to the $55 million in sales recorded in the fourth quarter of 2025.

Medincell, in partnership with Teva Pharmaceuticals, receives mid- to high-single-digit royalties on these sales and is also eligible for significant commercial milestones. UZEDY® is a long-acting injectable formulation of risperidone, approved for schizophrenia and bipolar I disorder.

Meanwhile, the application for marketing authorization for Olanzapine LAI, another treatment targeting schizophrenia, has been accepted by the US FDA, with a decision expected by the end of the year.